Page last updated: 2024-11-08
n(4)-acetylsulfadimethoxine
Description
N(4)-acetylsulfadimethoxine: major metabolite of sulfadimethoxine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
N(4)-acetylsulfadimethoxine : A sulfonamide that is benzenesulfonamide substituted by an acetylamino group at position 4 and a 4,6-dimethoxy-pyrimidin-2-yl group at the nitrogen atom. It is a metabolite of the sulfonamide antibiotic sulfadimethoxine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 168167 |
| CHEBI ID | 83456 |
| MeSH ID | M0115043 |
Synonyms (10)
| Synonym |
|---|
| n(4)-acetylsulfadimethoxine |
| 24341-30-8 |
| n-{4-[(4,6-dimethoxypyrimidin-2-yl)sulfamoyl]phenyl}acetamide |
| n-[4-[(4,6-dimethoxypyrimidin-2-yl)sulfamoyl]phenyl]acetamide |
| acetamide, n-(4-(((4,6-dimethoxy-2-pyrimidinyl)amino)sulfonyl)phenyl)- |
| CHEBI:83456 |
| 4-acetylamino-n-(4,6-dimethoxy-pyrimidin-2-yl)-benzenesulfonamide |
| n4-acetyl-sulfadimethoxine |
| DTXSID90891444 |
| Q27156840 |
Research Excerpts
Pharmacokinetics
Roles (1)
| Role | Description |
|---|
| marine xenobiotic metabolite | Any metabolite produced by metabolism of a xenobiotic compound in marine macro- and microorganisms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (3)
| Class | Description |
|---|
| sulfonamide | An amide of a sulfonic acid RS(=O)2NR'2. |
| acetamides | Compounds with the general formula RNHC(=O)CH3. |
| pyrimidines | Any compound having a pyrimidine as part of its structure. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (12)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 5 (41.67) | 18.7374 |
| 1990's | 6 (50.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.51
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 11.51 (24.57) | | Research Supply Index | 2.71 (2.92) | | Research Growth Index | 4.22 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |